These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 2069400)
41. Clinical significance of different serum tumor markers in gynecological malignancies. Paulick R; Caffier H; Horner G; Lang K; Filbry E Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031 [TBL] [Abstract][Full Text] [Related]
42. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors]. Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243 [TBL] [Abstract][Full Text] [Related]
43. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259 [TBL] [Abstract][Full Text] [Related]
44. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289 [TBL] [Abstract][Full Text] [Related]
45. CA54/61 as a marker for epithelial ovarian cancer. Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381 [TBL] [Abstract][Full Text] [Related]
46. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma]. Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408 [TBL] [Abstract][Full Text] [Related]
47. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
49. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer]. Paulick R; Kaesemann H; Caffier H Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919 [TBL] [Abstract][Full Text] [Related]
50. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397 [TBL] [Abstract][Full Text] [Related]
51. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance]. Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749 [TBL] [Abstract][Full Text] [Related]
52. [Application of monoclonal antibody OC 125 in gynecological oncology]. Wu AR; Wang EY; Wang XX; Jia XH; Li L Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653 [TBL] [Abstract][Full Text] [Related]
53. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer]. Lahousen M Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273 [TBL] [Abstract][Full Text] [Related]
54. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
55. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294 [TBL] [Abstract][Full Text] [Related]
56. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma. Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125 [TBL] [Abstract][Full Text] [Related]
57. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369 [TBL] [Abstract][Full Text] [Related]
58. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer]. Kobayashi H; Sumimoto K; Terao T; Kawashima Y Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396 [TBL] [Abstract][Full Text] [Related]
59. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer]. Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320 [TBL] [Abstract][Full Text] [Related]
60. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]